Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab for non-responsive celiac disease
2024-511213-38-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial in celiac disease and Non-Responsive Celiac Disease (NRCD) comparing Amlitelimab with Placebo (2 arms). Primary endpoint: Change in Villus Height to Crypt Depth Ratio. Planned start Oct 2024; status: authorised.
02
Drugs
amlitelimab
03
Conditions
celiac diseaseNon-Responsive Celiac Disease (NRCD)
Beyond the preview
Go deeper on 2024-511213-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511213-38-00.